stockrowTarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
Follow TARS
Alert me
Tarsus Pharmaceuticals, Inc. (TARS) Revenue
Tarsus Pharmaceuticals, Inc.'s revenue for fiscal 2025 was $451.4M, up 146.7% from $183.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $682.2M. Over the past ten years it has ranged from $17.4M (fiscal 2023) to $451.4M (fiscal 2025) — the current reading is the highest in ten years. Tarsus Pharmaceuticals, Inc. ranks 34th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $451.4M | 146.71% |
| FY2024 | $183.0M | 948.62% |
| FY2023 | $17.4M | (32.42%) |
| FY2022 | $25.8M | (54.73%) |
| FY2021 | $57.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $194.6M | 11.88% |
| Jun 2026 | $173.9M | 7.32% |
| Mar 2026 | $162.1M | 6.85% |
| Dec 2025 | $151.7M | 27.78% |
| 17 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $1.2B |
| TARS Tarsus Pharmaceuticals, Inc. | $682.2M |
| VRDN Viridian Therapeutics, Inc. compare | $26.3M |
| DNLI Denali Therapeutics Inc. compare | $22.6M |
| VKTX Viking Therapeutics, Inc. compare | — |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TARS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement